Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Santosh Bhusal, Sherilyn Diomampo & Marina N Magrey. (2016) Clinical utility, safety, and efficacy of pregabalin in the treatment of fibromyalgia. Drug, Healthcare and Patient Safety 8, pages 13-23.
Read now
Read now
Adam Lloyd, Chad S. Boomershine, Ernest H. Choy, Arthi Chandran & Gergana Zlateva. (2012) The cost-effectiveness of pregabalin in the treatment of fibromyalgia: US perspective. Journal of Medical Economics 15:3, pages 481-492.
Read now
Read now
S.M. Beard, N. Roskell, T.K. Le, Y. Zhao, A. Coleman, D. Ang & K. Lawson. (2011) Cost effectiveness of duloxetine in the treatment of fibromyalgia in the United States. Journal of Medical Economics 14:4, pages 463-476.
Read now
Read now
Articles from other publishers (14)
Insa Backhaus, Alice Mannocci & Giuseppe La Torre. (2019) A Systematic Review of Economic Evaluation Studies of Drug-Based Non-Malignant Chronic Pain Treatment. Current Pharmaceutical Biotechnology 20:11, pages 910-919.
Crossref
Crossref
Adrián Pérez-Aranda, Francesco D’Amico, Albert Feliu-Soler, Lance M. McCracken, María T. Peñarrubia-María, Laura Andrés-Rodríguez, Natalia Angarita-Osorio, Martin Knapp, Javier García-Campayo & Juan V. Luciano. (2019) Cost–Utility of Mindfulness-Based Stress Reduction for Fibromyalgia versus a Multicomponent Intervention and Usual Care: A 12-Month Randomized Controlled Trial (EUDAIMON Study). Journal of Clinical Medicine 8:7, pages 1068.
Crossref
Crossref
Margreet S. H. Wortman, Joran Lokkerbol, Johannes C. van der Wouden, Bart Visser, Henriëtte E. van der Horst & Tim C. olde Hartman. (2018) Cost-effectiveness of interventions for medically unexplained symptoms: A systematic review. PLOS ONE 13:10, pages e0205278.
Crossref
Crossref
Tinna Laufey Asgeirsdottir, Kristin Helga Birgisdottir, Thorhildur Ólafsdóttir & Sigurdur Pall Olafsson. (2017) A compensating income variation approach to valuing 34 health conditions in Iceland. Economics & Human Biology 27, pages 167-183.
Crossref
Crossref
Yvonne van Eijk-Hustings, Mariëlle Kroese, An Creemers, Robert Landewé & Annelies Boonen. (2015) Resource utilisation and direct costs in patients with recently diagnosed fibromyalgia who are offered one of three different interventions in a randomised pragmatic trial. Clinical Rheumatology 35:5, pages 1307-1315.
Crossref
Crossref
Juan V Luciano, Francesco D’Amico, Marta Cerdà-Lafont, María T Peñarrubia-María, Martin Knapp, Antonio I Cuesta-Vargas, Antoni Serrano-Blanco & Javier García-Campayo. (2014) Cost-utility of cognitive behavioral therapy versus U.S. Food and Drug Administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomized controlled trial. Arthritis Research & Therapy 16:5.
Crossref
Crossref
Tracy L. Skaer. (2014) Fibromyalgia: Disease Synopsis, Medication Cost Effectiveness and Economic Burden. PharmacoEconomics 32:5, pages 457-466.
Crossref
Crossref
Hiroyoshi Kino, Hiromichi Suzuki, Kazuhiro Nakamura, Takao Koiso, Yoshiro Ito, Kazuya Uemura & Akira Matsumura. (2014) <i>Clostridium difficile</i> Infection Induced by Pregabalin-associated Agranulocytosis. Internal Medicine 53:18, pages 2149-2152.
Crossref
Crossref
Héctor Arreola Ornelas, Alfonso Rosado Buzzo, Lourdes García, Javier Dorantes Aguilar, Iris Contreras Hernández & Joaquín F. Mould Quevedo. (2012) Cost-effectiveness Analysis of Pharmacologic Treatment of Fibromyalgia in Mexico. Reumatología Clínica (English Edition) 8:3, pages 120-127.
Crossref
Crossref
Héctor Arreola Ornelas, Alfonso Rosado Buzzo, Lourdes García, Javier Dorantes Aguilar, Iris Contreras Hernández & Joaquín F. Mould Quevedo. (2012) Análisis de coste-efectividad en el tratamiento farmacológico del síndrome de fibromialgia en México. Reumatología Clínica.
Crossref
Crossref
James P. Burke, Robert J. Sanchez, Ashish V. Joshi, Joseph C. Cappelleri, Mahesh Kulakodlu & Rachel Halpern. (2011) Health Care Costs in Patients with Fibromyalgia on Pregabalin vs. Duloxetine. Pain Practice 12:1, pages 14-22.
Crossref
Crossref
Thiru Mandyam Annaswamy, Arthur J. De Luigi, Bryan J. O'Neill, Nandita Keole & David Berbrayer. (2011) Emerging Concepts in the Treatment of Myofascial Pain: A Review of Medications, Modalities, and Needle-based Interventions. PM&R 3:10, pages 940-961.
Crossref
Crossref
Simon Hayhoe. (2011) Diagnosis and management of fibromyalgia: how and why. Pain Management 1:3, pages 267-275.
Crossref
Crossref
Anne Chamberlin Siler, Hallie Gardner, Keenan Yanit, Tera Cushman & Marian McDonagh. (2011) Systematic Review of the Comparative Effectiveness of Antiepileptic Drugs for Fibromyalgia. The Journal of Pain 12:4, pages 407-415.
Crossref
Crossref